Company profile
AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EPETRABOROLE | phase2_3 | — | 10 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05283746 | phase1 | completed | 2022-02-21 | 2022-06-10 | AN2 Therapeutics, Inc | A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function |
| NCT05995444 | phase1 | completed | 2023-06-05 | 2023-07-26 | AN2 Therapeutics, Inc | A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects |
| NCT07024589 | phase1 | completed | 2025-08-04 | 2026-03-14 | AN2 Therapeutics, Inc | First-in-Human Trial of Oral AN2-502998 |
| NCT04892641 | phase1 | completed | 2021-06-10 | 2022-02-26 | AN2 Therapeutics, Inc | Phase 1 Study of Epetraborole Tablets |
| NCT05327803 | phase2_3 | terminated | 2022-05-20 | 2024-12-18 | AN2 Therapeutics, Inc | Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease |
FDA applications (0)
No records yet.